195 related articles for article (PubMed ID: 15469393)
21. Recent advancement of molecular mechanisms of liver fibrosis.
Seki E; Brenner DA
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):512-8. PubMed ID: 25869468
[TBL] [Abstract][Full Text] [Related]
22. An update on the recent advances in antifibrotic therapy.
Tacke F; Weiskirchen R
Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1143-1152. PubMed ID: 30261763
[TBL] [Abstract][Full Text] [Related]
23. Hepatic stellate cells and the reversal of fibrosis.
Kisseleva T; Brenner DA
J Gastroenterol Hepatol; 2006 Oct; 21 Suppl 3():S84-7. PubMed ID: 16958681
[TBL] [Abstract][Full Text] [Related]
24. New Developments on the Treatment of Liver Fibrosis.
Koyama Y; Xu J; Liu X; Brenner DA
Dig Dis; 2016; 34(5):589-96. PubMed ID: 27332862
[TBL] [Abstract][Full Text] [Related]
25. Reversal of liver cirrhosis: current evidence and expectations.
Jung YK; Yim HJ
Korean J Intern Med; 2017 Mar; 32(2):213-228. PubMed ID: 28171717
[TBL] [Abstract][Full Text] [Related]
26. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis.
Kim WH; Matsumoto K; Bessho K; Nakamura T
Am J Pathol; 2005 Apr; 166(4):1017-28. PubMed ID: 15793283
[TBL] [Abstract][Full Text] [Related]
27. Activation of autophagy is required for Oroxylin A to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation.
Chen W; Zhang Z; Yao Z; Wang L; Zhang F; Shao J; Chen A; Zheng S
Int Immunopharmacol; 2018 Mar; 56():148-155. PubMed ID: 29414645
[TBL] [Abstract][Full Text] [Related]
28. Antifibrotic action of telmisartan in experimental carbon tetrachloride-induced liver fibrosis in Wistar rats.
Ionică FE; Mogoantă L; Nicola GC; ChiriŢă C; Negreş S; Bejenaru C; Turculeanu A; Badea O; Popescu NL; Bejenaru LE
Rom J Morphol Embryol; 2016; 57(4):1261-1272. PubMed ID: 28174792
[TBL] [Abstract][Full Text] [Related]
29. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
Nishikawa K; Osawa Y; Kimura K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308992
[TBL] [Abstract][Full Text] [Related]
30. Hepatoprotective Effects of Grape Seed Procyanidin B2 in Rats With Carbon Tetrachloride-induced Hepatic Fibrosis.
Wang Z; Zhang Z; Du N; Wang K; Li L
Altern Ther Health Med; 2015; 21 Suppl 2():12-21. PubMed ID: 26308756
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
Ma R; Chen J; Liang Y; Lin S; Zhu L; Liang X; Cai X
Biomed Pharmacother; 2017 Apr; 88():459-468. PubMed ID: 28122312
[TBL] [Abstract][Full Text] [Related]
32. Addressing liver fibrosis with liposomes targeted to hepatic stellate cells.
Adrian JE; Poelstra K; Kamps JA
J Liposome Res; 2007; 17(3-4):205-18. PubMed ID: 18027241
[TBL] [Abstract][Full Text] [Related]
33. [Mechanism of action of Yiqi Huoxue Recipe in regulating autophagy and reversing liver fibrosis].
Wang BY; Zhao W; Niu XM; Du JH; Fu N; Zhao SX; Wang Y; Wang RQ; Zhang YG; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2017 May; 25(5):365-370. PubMed ID: 28763844
[No Abstract] [Full Text] [Related]
34. Developing strategies for liver fibrosis treatment.
Murphy F; Arthur M; Iredale J
Expert Opin Investig Drugs; 2002 Nov; 11(11):1575-85. PubMed ID: 12437504
[TBL] [Abstract][Full Text] [Related]
35. Novel targeted therapies for the management of liver fibrosis.
Trivella JP; Martin P; Carrion AF
Expert Opin Emerg Drugs; 2020 Mar; 25(1):59-70. PubMed ID: 32098512
[No Abstract] [Full Text] [Related]
36. [Cellular mechanism in the fibrogenesis of liver fibrosis].
You H; Sun YM
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):563-4. PubMed ID: 23227528
[No Abstract] [Full Text] [Related]
37. Antioxidant and anti-inflammatory activities of berberine attenuate hepatic fibrosis induced by thioacetamide injection in rats.
Eissa LA; Kenawy HI; El-Karef A; Elsherbiny NM; El-Mihi KA
Chem Biol Interact; 2018 Oct; 294():91-100. PubMed ID: 30138605
[TBL] [Abstract][Full Text] [Related]
38. Curcumin modulates cannabinoid receptors in liver fibrosis in vivo and inhibits extracellular matrix expression in hepatic stellate cells by suppressing cannabinoid receptor type-1 in vitro.
Zhang Z; Guo Y; Zhang S; Zhang Y; Wang Y; Ni W; Kong D; Chen W; Zheng S
Eur J Pharmacol; 2013 Dec; 721(1-3):133-40. PubMed ID: 24076327
[TBL] [Abstract][Full Text] [Related]
39. Bioconjugation of oligonucleotides for treating liver fibrosis.
Ye Z; Houssein HS; Mahato RI
Oligonucleotides; 2007; 17(4):349-404. PubMed ID: 18154454
[TBL] [Abstract][Full Text] [Related]
40. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats.
Zhao TY; Su LP; Ma CY; Zhai XH; Duan ZJ; Zhu Y; Zhao G; Li CY; Wang LX; Yang D
BMC Gastroenterol; 2015 Jul; 15():77. PubMed ID: 26152281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
